Evidence map›Paper›PMID 36479278›Full record

ArticleTransplantation direct2022

Baseline Characteristics and Representativeness of Participants in the BEST-Fluids Trial: A Randomized Trial of Balanced Crystalloid Solution Versus Saline in Deceased Donor Kidney Transplantation.

Michael G Collins, Magid A Fahim, Elaine M Pascoe, Carmel M Hawley, David W Johnson, Julie Varghese, Laura E Hickey, Philip A Clayton, John S Gill, Kathryn B Dansie and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 14 institutions in 3 countries.

Michael G CollinsCentral Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Magid A FahimAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Elaine M PascoeAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Carmel M HawleyAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
David W JohnsonAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Julie VargheseAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Laura E HickeyAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Philip A ClaytonCentral Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
John S GillDivision of Nephrology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Kathryn B DansieFaculty of Medical and Health Sciences, The University of Adelaide, Adelaide, Australia.
Rachael C McConnochieDepartment of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.
Liza A VergaraAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Charani KiriwandeniyaAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Donna ReidlingerAustralasian Kidney Trials Network, The University of Queensland, Brisbane, Australia.
Peter F MountDepartment of Nephrology, Austin Health, Melbourne, Australia.
Laurence WeinbergDepartment of Anaesthesia, Austin Health, Melbourne, Australia.
Colin J McArthurDepartment of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.
P Toby CoatesCentral Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Zoltan H EndreDepartment of Nephrology, Prince of Wales Hospital, Randwick, Sydney, Australia.
David GoodmanDepartment of Nephrology, St. Vincent's Hospital, Melbourne, Australia.
Kirsten HowardSchool of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Martin HowellSchool of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Jagadish S JambotiDepartment of Nephrology and Renal Transplantation, Fiona Stanley Hospital, Murdoch, WA, Australia.
John KanellisDepartment of Nephrology, Monash Health, Clayton, Victoria, Australia.
Jerome M LaurenceInstitute of Academic Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.
Wai H LimSchool of Medicine, University of Western Australia, Perth, WA, Australia.
Steven J McTaggartChild and Adolescent Renal Service, Queensland Children's Hospital, Brisbane, QLD, Australia.
Philip J O'ConnellCentre for Transplant and Renal Research, Westmead Institute for Medical Research, University of Sydney, NSW, Australia.
Helen L PilmoreDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
Germaine WongSchool of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Steven J ChadbanDepartment of Renal Medicine, Kidney Centre, Royal Prince Alfred Hospital, Sydney, Australia.
The University of Queensland · AUAuckland City Hospital · NZUniversity of British Columbia · CAKidney Health Australia · AURoyal Adelaide Hospital · AUSouth Australian Health and Medical Research Institute · AUAustin Health · AUPrincess Alexandra Hospital · AURoyal Prince Alfred Hospital · AUSt Vincent's Hospital Melbourne · AUThe University of Melbourne · AUThe University of Sydney · AUThe University of Western Australia · AUTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delayed graft function (DGF) is a major complication of deceased donor kidney transplantation. Saline (0.9% sodium chloride) is a commonly used intravenous fluid in transplantation but may increase the risk of DGF because of its high chloride content. Better Evidence for Selecting Transplant Fluids (BEST-Fluids), a pragmatic, registry-based, double-blind, randomized trial, sought to determine whether using a balanced low-chloride crystalloid solution (Plasma-Lyte 148) instead of saline would reduce DGF. We sought to evaluate the generalizability of the trial cohort by reporting the baseline characteristics and representativeness of the trial participants in detail. Methods: We compared the characteristics of BEST-Fluids participants with those of a contemporary cohort of deceased donor kidney transplant recipients in Australia and New Zealand using data from the Australia and New Zealand Dialysis and Transplant Registry. To explore potential international differences, we compared trial participants with a cohort of transplant recipients in the United States using data from the Scientific Registry of Transplant Recipients. Results: During the trial recruitment period, 2373 deceased donor kidney transplants were performed in Australia and New Zealand; 2178 were eligible' and 808 were enrolled in BEST-Fluids. Overall, trial participants and nonparticipants were similar at baseline. Trial participants had more coronary artery disease (standardized difference [d] = 0.09; Conclusions: BEST-Fluids participants had more comorbidities and received slightly fewer high-risk deceased donor kidneys but were otherwise representative of Australian and New Zealand transplant recipients and were generally similar to US recipients. The trial results should be broadly applicable to deceased donor kidney transplantation practice worldwide.

Identifiers

PMID36479278
PMCPMC9722559
OpenAlexW4311023473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.